LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · 2 straight earnings beats
No insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $15K to $50K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 27, 2026
Period ending
Sep 30, 2026
Earnings per share
$2.24 expected
Revenue
Financial statements: Alpha Vantage
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 27, 2026 | $2.46est. $2.24 | +9.74%beat | $15.03BAlpha Vantage | +4.7%from $14.36B |
| Jun 30, 2026Reported Jul 21, 2026 | $2.41est. $2.15 | +12.21%beat | $14.42BAlpha Vantage | -2.8%from $14.84B |
| Mar 31, 2026Reported Apr 28, 2026 | $1.99est. $2.07 | -3.68%miss | $13.52BAlpha Vantage | -0.7%from $13.62B |
| Dec 31, 2025Reported Feb 4, 2026 | $2.03est. $2.00 | +1.27%beat | $13.33BAlpha Vantage | -1.6%from $13.56B |
| Sep 30, 2025Reported Oct 28, 2025 | $2.25est. $2.31 | -2.60%miss | $14.36BAlpha Vantage | +9.0%from $13.17B |
| Jun 30, 2025Reported Jul 17, 2025 | $2.42est. $2.37 | +2.11%beat | $14.84BAlpha Vantage | +15.3%from $12.87B |
| Mar 31, 2025Reported Apr 29, 2025 | $2.28est. $2.17 | +5.07%beat | $13.62BAlpha Vantage | +12.4%from $12.12B |
| Dec 31, 2024Reported Jan 31, 2025 | $1.98est. $1.76 | +12.50%beat | $13.56BAlpha Vantage | +15.1%from $11.78B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $13.33B | $13.52B | $14.42B | $15.03B |
| Cost of what it sold | $3.54B | $3.46B | $3.68B | $3.61B |
| Gross profit | $9.79B | $10.06B | $10.74B | $11.42B |
| What it spent | ||||
| Research and development | $2.84B | $2.74B | $2.76B | $5.15B |
| Sales and admin | $3.44B | $3.14B | $3.24B | $3.08B |
| Other operating costs | — | — | — | $1.35B |
| Total operating expenses | $6.27B | $5.83B | $6.00B | $9.58B |
| What was left | ||||
| Operating profit | $3.52B | $4.24B | $4.74B | $1.84B |
| Interest on debt | $304.0M | $343.0M | $462.3M | $468.0M |
| Profit before tax | $3.22B | $3.84B | $4.27B | $1.32B |
| Tax | $813.9M | $683.0M | $1.01B | $121.0M |
| Net profit | $2.41B | $3.16B | $3.27B | $1.20B |
| EBITDA | $5.07B | $5.41B | $5.94B | $5.37B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bearish
Novo, Novartis drugs cut heart-risk markers but not cardiovascular events
BearishNov 10Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
Leans bullishNov 10Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
NeutralNov 10Four planned note series guaranteed by Novartis (NVS) carry a $2,000 minimum denomination.
NeutralNov 9Form 424B5 Novartis Capital CORP Filed by: NOVARTIS AG
NeutralNov 9Novartis's Lp(a) drug cut the marker 78% but did nothing for heart attacks or strokes, full HORIZON data show
BearishNov 7Novartis shelves potential blockbuster pelacarsen as landmark study fails
NeutralNov 7Novartis Reports Nine Cases of Tumors Caused by Gene Therapy
BearishNov 7
